Vijaya Diagnostic Centre Limited
Financial trend (95/100) does the heavy lifting; valuation (1/100) is the drag.
ExpensiveOvervaluedOur blended model reads Vijaya Diagnostic Centre Limited as a Hold at 45/100. At ₹1,344.4 it trades above our blended DCF and relative-multiples fair value of ₹672.2, about 50% downside to that estimate — we read it as overvalued by 50%. On 78.0x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 5% below its 52-week high of ₹1,412.5 and 56% above the low of ₹861.4. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹1,379.2 implies about 3% upside across 10 analysts. It clears 9 of 13 investability checks, with durability 85, valuation 1 and momentum 83 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹537.76.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-4.82% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 19.7%
- Pass: Low debt (D/E < 0.5): 0.44x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 27%
- Pass: Earnings growing: 38%
- Pass: Net margin ≥ 10%: 21.2%
- Pass: Current ratio > 1.5: 2.60
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 16.1
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter52.5%
- Institutions37.4%
- Public & other10.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (19.7%).
- Healthy profit margin (21.2%).
- Financially solid — Altman Z 16.1.
Opportunities
- Earnings growing (38% YoY).
- Revenue growing (27% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited operates diagnostic facilities across India, offering laboratory services spanning clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics. The company provides imaging services including CT, MRI, MRI-3T, ultrasound, and X-ray, alongside cardiology, gastroenterology, nuclear medicine, and PET/CT services. It also offers health checkups and home-based sample collection.
Vijaya Diagnostic Centre Limited — frequently asked questions
Is Vijaya Diagnostic Centre Limited a buy, hold or sell?
StocksWizard currently rates Vijaya Diagnostic Centre Limited (VIJAYA) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Vijaya Diagnostic Centre Limited's fair value?
Our blended DCF and relative-valuation model estimates Vijaya Diagnostic Centre Limited's fair value at about ₹672.2, versus a current price of ₹1,344.4 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Vijaya Diagnostic Centre Limited financially healthy?
Vijaya Diagnostic Centre Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Vijaya Diagnostic Centre Limited's share price performed?
Vijaya Diagnostic Centre Limited is up 14% over three months, and last traded at ₹1,344.4. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.